Clinical Trials Browser

Pathologic Complete Response × cc-486 × Clear all

NCT01757535 2025-07-08

QUAZAR AML-001

Phase 3 Completed

472 enrolled 24 charts 1 FDA

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT06180863 2023-12-26

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Phase 2 Withdrawn

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute